Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab in Rheumatoid Arthritis (CREDO 4)
NCT03120949Phase 3Completed
- Sponsor
- R-Pharm
- Start
- Jul 2017
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of olokizumab in rheumatoid arthritis (RA), sponsored by R-Pharm. Started Jul 2017; status: completed.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03120949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03120949.